Lepu Scientech’s ScienCcrown TAVR System Earns NMPA Medical Device License
Lepu Scientech Medical Technology (Shanghai) Co., Ltd (HKG: 2291), a leading China-based medical technology company,...
Eli Lilly’s Kisunla Receives NMPA Approval for Early Alzheimer’s Disease Treatment
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...
BioNova Pharmaceuticals’ BN104 Receives Breakthrough Therapy Designation in China
The China’s Center for Drug Evaluation (CDE) website has indicated that BioNova Pharmaceuticals (Shanghai) Ltd.’s...
Evopoint Biosciences Submits Pre-NDA for Funobactam, Imipenem, and Cilastatin to NMPA
Suzhou-based Evopoint Biosciences Co., Ltd. has announced the submission of a Pre-NDA (New Drug Application)...
Xtalpi Inc. Partners with Gnosis Neurodynamics to Develop Neural Drug Screening Platform
Shenzhen-based QuantumPharm Inc., trading as Xtalpi Inc. (HKG: 2228), has announced a strategic partnership with...
GSK’s Blenrep and Star Pharma’s Topiramate Solution Target Priority Review in China
The China’s Center for Drug Evaluation (CDE) website has signaled that GlaxoSmithKline’s (GSK; NYSE: GSK)...
Sciwind Biosciences’ Ecnoglutide Accepted for Review by NMPA for Weight Management
Sciwind Biosciences Co., Ltd has received a significant boost as the National Medical Products Administration...
Blackstone and Bain Capital Submit Final Bids for Mitsubishi Tanabe Pharma
In a significant development in the alternative asset management sector, companies such as Blackstone and...
Everest Medicines’ Velsipity NDA for Ulcerative Colitis Accepted by China’s NMPA
China-based Everest Medicines (HKG: 1952) has announced that the National Medical Products Administration (NMPA) has...
AstraZeneca’s ALXN2350 Selected for CDE’s Rare Disease Drug Development Program
The Center for Drug Evaluation (CDE) in China has announced its intention to include AstraZeneca’s...
NMPA’s CDE Releases Draft Proposal for Benefit-Risk Assessment in Global Drug Development
The Center for Drug Evaluation of the National Medical Products Administration (NMPA) has issued the...
Perennial Real Estate Holdings’ Tianjin Hospital Earns Medical Practice License
Singapore-based Perennial Real Estate Holdings Limited has announced that its Perennial General Hospital in Tianjin...
MSD Halts Development of Vibostolimab and Favezelimab Due to Trial Setbacks
US pharmaceutical giant Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed its decision to...
Adcendo ApS Expands Partnership with Biocytogen to Enhance ADC Pipeline
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has...
MicroPort CardioFlow’s VitaFlow Liberty Receives Marketing Approval in Turkey
China-based MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) has announced that its second-generation transcatheter aortic...
Vcanbio’s VUM02 Secures NMPA Approval and FDA ODD for Cirrhosis and aGvHD
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced significant progress for...
Novo Nordisk Invests DKK 8.5 Billion in New Odense Manufacturing Facility
Denmark-based pharmaceutical giant Novo Nordisk A/S (NYSE: NVO) is making a significant investment in its...
Johnson & Johnson Submits sBLA to FDA for Simponi in Pediatric Ulcerative Colitis
US pharmaceutical major Johnson & Johnson (J&J, NYSE: JNJ) has announced the submission of a...
J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment
Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...
Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment
Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...